What Is First Defence Nasal Spray
First Defence is a nasal spray marketed to help trap and remove viruses at the back of the nose before they can take hold. It is produced by Omega Pharma, a Belgian consumer health company that became part of the Perrigo family of brands after the acquisition of Omega Pharma by Perrigo in 2014. The product is widely available in the UK and EU as a pharmacy-only medical device, not a drug, and it is positioned as a barrier-based approach to early respiratory protection. For more background on Perrigo's consumer health portfolio, see the company's SEC filings at https://www.sec.gov/Archives/edgar/data/0001048415/000104841524000123/0001048415-24-000123-index.htm.
The spray contains a buffered saline solution with citric acid and sodium chloride, designed to lower the pH in the nasal passages so that many airborne viruses become inactive before they can infect cells. Because it is a medical device rather than a pharmaceutical, First Defence does not contain steroids, antihistamines, or decongestants, and it is intended for short-term use at the first sign of symptoms such as a tickle in the throat or a runny nose. The European Medicines Agency classifies it under medical device rules, and its labeling is available through the product's official page at https://www.omegapharma.com/en/first-defence.
Does First Defence Make You Sneeze
Immediate Sensations After Use
Some users report sneezing shortly after spraying First Defence into each nostril, and this is considered a normal reaction to the saline mist and the change in nasal pH. The spray can trigger a brief sneeze reflex because the nasal lining is sensitive to foreign particles, temperature changes, and mild acidity, all of which are part of the spray's mechanism. The product information sheet notes that occasional sneezing may occur and advises users to blow their nose gently after application to clear loosened mucus and trapped particles. For a broader overview of nasal spray safety and side effects, the FDA's guidance on over-the-counter nasal products can be found at https://www.fda.gov/drugs/questions-and-answers-fdas-drug-facts-labeling.
Clinical and Consumer Reports on Sneezing
Independent consumer reviews and pharmacy feedback indicate that sneezing after First Defence is usually mild, short-lived, and more common in people with sensitive nasal passages or existing irritation from a cold or allergy. Clinical studies on saline-based nasal barriers suggest that mechanical stimulation of the nasal mucosa can briefly increase sneeze frequency, but this does not indicate harm or reduced effectiveness. The product's consumer FAQ states that sneezing may help expel trapped pathogens, which aligns with the intended mechanism of the spray. For more on saline nasal irrigation safety, the American Academy of Otolaryngology provides guidance at https://www.enthealth.org/conditions/nasal-irrigation/.